We aim to use science for the benefit of human kind, and we aim for our science to have an impact. Our scientific discoveries build upon the work of previous great minds and the development of many molecular techniques, scientific methods, and technological breakthroughs, we have been able to contribute with novel insights within toxinology and antivenom development to the scientific community and society. With the support from generous donors, we have been able to make much of our work publicly available via publication in international peer-reviewed journals.

Peer-reviewed publications


Laustsen AH, Johansen KH, Engmark M, Andersen MR. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? PLoS Neglected Tropical Diseases 2017, 11; e0005361.
Laustsen AH, Engmark M, Clouser C, Timberlake S, Vigneault F, Gutiérrez JM, Lomonte B. Exploration of immunoglobulin transcriptomes from mice immunized with three­‐finger toxins and phospholipases A2 from the Central American coral snake, Micrurus nigrocinctus. PeerJ 2017, 5; e2924.
Laustsen AH, Lauridsen LP, Lomonte B, Andersen MR, Lohse B. Pitfalls to avoid when using phage display for snake toxins. Toxicon 2017, 126; p79-89.
Lauridsen LP, Laustsen AH, Lomonte B, Gutiérrez JM. Exploring the venom of the forest cobra snake: Toxicovenomics and antivenom profiling of Naja melanoleuca. Journal of Proteomics 2017, 150; p98-108.


Engmark M, Andersen MR, Laustsen AH, Patel J, Sullivan E, de Masi F, Hansen CS, Kringelum JV, Lomonte B, Gutiérrez JM, Lund O. High-throughput immuno-profiling of mamba (Dendroaspis) venom toxin epitopes using high-density peptide microarrays. Scientific Reports 2016, 6; 36629.
Laustsen AH. Costing recombinant antivenoms. Nature 2016, 538; p41
Laustsen AH. Toxin synergism in elapid snake venoms. Toxin Reviews 2016, 35; p165-170.
Laustsen AH, Solà M, Jappe EC, Oscoz S, Lauridsen LP, Engmark M. Biotechnological trends in spider and scorpion antivenom development. Toxins 2016, 8; p1-33
Laustsen AH. Recombinant antivenoms. PhD thesis. University of Copenhagen, Denmark. ISBN 978‐87­‐93086­‐61‐6.
Laustsen AH, Engmark M, Milbo C, Johannesen J, Lomonte B, Gutiérrez JM, and Lohse B. From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy. Current Pharmaceutical Design 2016, 22; p5270-5293.
Lauridsen LP, Laustsen AH, Lomonte B, Gutiérrez JM. Toxicovenomics and antivenom profiling of the Eastern green mamba snake (Dendroaspis angusticeps). Journal of Proteomics 2016, 136; p248-261.


Laustsen AH, Gutiérrez JM, Rasmussen AR, Engmark M, Gravlund P, Sanders KL, Lohse B, Lomonte B. Danger in the reef: Proteome, toxicity, and neutralization of the venom of the olive sea snake, Aipysurus laevis. Toxicon 2015, 107; p187-196.
Laustsen AH, Lohse B, Lomonte B, Engmark M, Gutiérrez JM. Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score. Toxicon 2015, 104; p43-45.
Laustsen AH, Gutiérrez JM, Lohse B, Rasmussen AR, Fernández J, Milbo C, and Lomonte B. Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxins. Toxicon 2015, 99; p23-35.
Laustsen AH, Lomonte B, Lohse B, Fernández J, Gutiérrez JM. Unveiling the nature of black mamba (Dendroaspis polylepis) venom through venomics and antivenom immunoprofiling: Identification of key toxin targets for antivenom development. Journal of Proteomics 2015, 119; p126-142.


Novo Nordisk Foundation

Development of a recombinant antibody-based treatment of snakebites.

DKK 2,100,000

Human oligoclonal recombinant antivenoms.

DKK 1,695,876


Symphogen A/S

Otto Mønsteds Fond


Knud Højgaards Fond

Oticon Fonden


Popular science publications


Laustsen AH, Knudsen C, Øhlenschlæger M. Slangearters gift er unikke cocktails af dræberproteiner. Videnskab 2017.


Laustsen AH, Engmark M. How biotechnology could offer hope for snakebite victims. The Conversation 2016.